Navigation Links
Express Plus Clinical Chemistry Analyzer

ProductsExpress Plus Clinical Chemistry Analyzer
Company Siemens Medical Solutions Diagnostics
Item Express Plus Clinical Chemistry Analyzer
Features 
  • Patient Oriented Random Access operation for maximum productivity and rapid response times
  • Bar-coded samples and reagents eliminate handling errors
  • A throughput of up to 180 tests per hour together with automatic on-board supplies management gives the operator over 1 hour of unattended operation
  • Multi-language screen options, printouts and keyboard characters ensure ease of use in all locations
  • Quality control program includes Levey Jennings graph and westgard rules
  • Data management capability with bi-directional interface, preprograms up to 48 tests and 360 patients
  • Simple user interface with menu-related functional keys for worklist entry via keyboard, bar-code sheet or download
  • Rapid response for STAT samples
  • One hour walk-away capability
  • 40 position serum cup tray or 20 position primary tube tray
  • Automatic predilution up to 1:100
  • Auto rerun of samples
  • Sample and reagent level detection.
Description The Express Plus clinical chemistry analyzer is a fully automated walk away system designed for maximum productivity, convenience and reliability.
Info Siemens Medical Solutions Diagnostics
Customer Service: 800-255-3232 or 914-631-8000
Web site: http://www.siemens.com/diagnostics-products

Related medicine products :

1. Smith Expressor Hook
2. Opti-Free Express No Rub
3. Expressions Accents
4. Expressions colors
5. My Vision Express Software
6. ICP Express I.E.C.
7. ICP Express Monitoring System
8. Express Plus
9. Express Elyte Systems
10. Express Coronary Stent System
11. TAXUS Express2 Over-the-wire Paclitaxel-Eluting Coronary Stent System
... the right product for any patient ranging from pe...patients with tracheotomies. These products offer ...itical care applications., ,The Unti-Mist HME and...ts and staff members. This entire product line of ...
Combination heat and moisture exchanger and bacterial/viral filters for Anesthesia and Respiratory applications.
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to
Indications For Usage: ,Pediatric (recommended tidal volume 70-250ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intend
Medicine Products:
(Date:12/3/2008)...udy suggests need to change therapeutic guidelines...ws) -- A pill that contains two blood pressure dru...gy in reducing the risk of serious cardiovascular ...ure, according to a study that included more than ...ay, Denmark and Finland. , The patients took ei...
(Date:12/3/2008)... Cellastim, an animal-free ...ia, can outperform animal and human derived serum ...rt Collins, CO (PRWEB) December 3, 2008 -- Cellast... derived albumin in CHO media and can improve both...lines across a variety of chemically defined media...
(Date:12/3/2008)...ICAGO, Dec. 3 The gold ...his is the 26th year gold has been dropped into th...past weekend. The one-ounce 2005 Liberty $50 coin ...ion Army red kettle at a Jewel Food Store in Norri...sited in McHenry County in 1982, The Salvation Arm...
(Date:12/3/2008)...MWOOD PARK, N.J., Dec. 3 ...: HLTH ) and its 84% owned subsidiary, WebMD Hea... Annual Meetings of Stockholders beginning at 9:30.... , , A live audio webcast of the meeting...o the audio webcast of the meetings, investors can...
Breaking Medicine News(10 mins):Health News:Blood Pressure Pill Combo More Effective Than Diuretics 2Health News:InVitria's Cellastim Delivers Superior Results in CHO Cell Culture 2Health News:HLTH Corporation and WebMD to Webcast Annual Meetings of Stockholders 2
...t get training posts through the flawed Medical Tr...er misery because the government// is stalling on ... BMA warns. Latest figures show that 34,250 docto...ing posts in the UK. The government has so far giv...
... (CFS) has been associated with altered amounts of...troencephalograph// (EEG) activity and impaired sl...the journal SLEEP finds that CFS is also associate... sleep challenge, suggesting an impairment of the ...
...origin optician who was part of a British charity,... volunteering// in India. Premal Patel, who was p...harity, carried out a record 850 eye examinations ... of Bangalore in March. The charity helps people ...
...ls are setting new trends in drug abuse- drugs suc...isused//, a report has shown. Teen boys have been...g a slice of the vice, teen girls have become a ca...cription drugs, according to the White House Offic...
Other Medicine News:Health News:Junior Doctors Facing More Misery Because of Contract Deadlock: BMA 2
(Date:12/2/2008)...Calif., Dec. 2 TorreyPines Therape...tive results from a 26 patient Phase II trial eval...rostomia, or dry mouth, in patients with Sjogren,s...tatistically significant increase in salivary flow...: 10 mg, 15 mg, and 20 mg. These doses were safe a...
(Date:12/2/2008)...Md., Dec. 2 Micromet, In...developing novel, proprietary antibodies for the t...seases, today announced that it has entered into a...ng Facility (CEFF) with Kingsbridge Capital Limite... the agreement, Kingsbridge has committed to provi...
(Date:12/1/2008)... , CHICAGO, Dec. 2 ...phy (PEM), a new technique for imaging the breast,...an,s hormonal status, two factors that limit the e...tecting cancer. Results will be presented today at... North America (RSNA). , , "The ability of...
(Date:12/1/2008)... Dec. 1 TargeGen has announced tha...om a multi-center, US-based clinical,trial of TG1...een scheduled at,the 2008 American Society of Hem...resentation are as follows:, Title: ...ilable, JAK2-Selective Inh...
Breaking Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4China Sky One Medical Inc Develops Nasal Spray for Rheumatic Disease 7149 1China Sky One Medical Inc Develops Nasal Spray for Rheumatic Disease 7149 2China Sky One Medical Inc Develops Nasal Spray for Rheumatic Disease 7149 3Abbott and AstraZeneca Expand Relationship to Include Co Promotion of CRESTOR 28R 29 7146 1Abbott and AstraZeneca Expand Relationship to Include Co Promotion of CRESTOR 28R 29 7146 2Abbott and AstraZeneca Expand Relationship to Include Co Promotion of CRESTOR 28R 29 7146 3Abbott and AstraZeneca Expand Relationship to Include Co Promotion of CRESTOR 28R 29 7146 4PAREXEL Closes the Acquisition of ClinPhone 7145 1PAREXEL Closes the Acquisition of ClinPhone 7145 2PAREXEL Closes the Acquisition of ClinPhone 7145 3PAREXEL Closes the Acquisition of ClinPhone 7145 4PAREXEL Closes the Acquisition of ClinPhone 7145 5Derma Sciences Reports Second Quarter 2008 Results 7142 1Derma Sciences Reports Second Quarter 2008 Results 7142 2Derma Sciences Reports Second Quarter 2008 Results 7142 3Derma Sciences Reports Second Quarter 2008 Results 7142 4Derma Sciences Reports Second Quarter 2008 Results 7142 5
...NG, Pa., June 19, 2007 /PRNewswire-FirstCall/ --,G...esent a poster,on trodusquemine (MSI-1436), its no...betes Association (ADA) 67th Scientific,Sessions, ..., is titled, "Trodusquemine is a Multiple,Pathway ...duces,Adiposity, and Improves Plasma Insulin and L...
... abstracts highlight VELCADE efficacy in broad ran...MBRIDGE, Mass., June 19, 2007 /PRNewswire-FirstCal...nced that data for,VELCADE, the market leading the...tients with previously treated multiple myeloma,(M... Myeloma,Workshop (IMW) in Kos, Greece, June 25-30...
Other Medicine Technology:Genaera to Present Preclinical Data on Trodusquemine for the,Treatment of Obesity at the American Diabetes Association 67th,Scientific Sessions 2Genaera to Present Preclinical Data on Trodusquemine for the,Treatment of Obesity at the American Diabetes Association 67th,Scientific Sessions 3Genaera to Present Preclinical Data on Trodusquemine for the,Treatment of Obesity at the American Diabetes Association 67th,Scientific Sessions 4Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 3Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 4Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 5Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 7Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 8